Home Cart Sign in  
Chemical Structure| 1421373-66-1 Chemical Structure| 1421373-66-1

Structure of Osimertinib mesylate
CAS No.: 1421373-66-1

Chemical Structure| 1421373-66-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. It overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Synonyms: AZD-9291 mesylate; Mereletinib mesylate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Osimertinib mesylate

CAS No. :1421373-66-1
Formula : C29H37N7O5S
M.W : 595.71
SMILES Code : C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O.CS(=O)(O)=O
Synonyms :
AZD-9291 mesylate; Mereletinib mesylate
MDL No. :MFCD28137994
InChI Key :FUKSNUHSJBTCFJ-UHFFFAOYSA-N
Pubchem ID :78357807

Safety of Osimertinib mesylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Osimertinib mesylate

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Description
Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible EGFR inhibitor selective for mutant forms, with an IC50 of 12 nM against the L858R mutation and 1 nM against the L858R/T790M mutation. Otherwise, Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].
Target
  • EGFR/ErbB1

In Vitro:

Cell Line
Concentration Treated Time Description References
PC9 1uM 24 h To evaluate the effect of Osimertinib on EGFR, AKT, and ERK signaling pathways, results showed that in resistant cells, EGFR signaling was suppressed, but ERK and AKT signaling was enhanced, and apoptosis was reduced. PMC6324945
H1975 1uM 24 h To evaluate the effect of Osimertinib on EGFR, AKT, and ERK signaling pathways, results showed that in resistant cells, EGFR signaling was suppressed, but ERK and AKT signaling was enhanced, and apoptosis was reduced. PMC6324945
HCC827 0.01–2 µM 3 days To observe the acute treatment response of HCC827 cells to Osimertinib, it was found that a subpopulation of tumor cells survived the initial treatment. PMC6750230
HCC827 160 nM 2–3 weeks To observe the survival of HCC827 cells under continuous exposure to 160 nM Osimertinib, it was found that a small percentage of cells could survive for more than 2-3 weeks. PMC6750230
NCI-H1975 12 nM 72 h To evaluate the antiproliferation activity of ASK120067 on tumor cells harboring EGFR T790M mutation, the results showed that ASK120067 has potent antiproliferation activity on NCI-H1975 cells. PMC7218543
PC-9 6 nM 72 h To evaluate the antiproliferation activity of ASK120067 on tumor cells harboring EGFR T790M mutation, the results showed that ASK120067 has potent antiproliferation activity on PC-9 cells. PMC7218543
HCC827 2 nM 72 h To evaluate the antiproliferation activity of ASK120067 on tumor cells harboring EGFR T790M mutation, the results showed that ASK120067 has potent antiproliferation activity on HCC827 cells. PMC7218543
H1975 cells 0.1 μM 72 h Osimertinib inhibited the growth of H1975 cells by 28 ± 13% PMC8419812
EGFR-mutant lung adenocarcinoma cells 0.1 μM 72 h Osimertinib inhibited the growth of EGFR-mutant lung adenocarcinoma cells by 81 ± 15% PMC8419812
PC9, H1975, HCC827, HCC2935 500 nM 21 days RNA-seq analysis revealed significant changes in gene expression regulation in osimertinib DTPs, particularly upregulation of EMT-related pathways and downregulation of cell cycle and MAPK signaling pathways. PMC9794691
PC9, H1975, HCC827, HCC2935 500 nM 24 days ATAC-seq analysis revealed significant changes in chromatin accessibility in osimertinib DTPs, particularly upregulation of EMT-related pathways and downregulation of tyrosine kinase signaling pathways. PMC9794691
PC9 cells 2 μM 9 days To evaluate the role of YAP in drug tolerance, an increase in YAP nuclear localization was observed. PMC11068778
H1975 cells 2 μM 9 days To evaluate the role of YAP in drug tolerance, an increase in YAP nuclear localization was observed. PMC11068778
HCC4006 100 nM 48 h To evaluate the synergistic effect of AZ1366 with EGFR inhibitors, results showed that AZ1366 enhanced the anti-proliferative effect of gefitinib. PMC5354947
HCC4006 100 nM 7 days To evaluate the long-term anti-proliferative effect of AZ1366 in combination with gefitinib, results showed that AZ1366 enhanced the anti-proliferative effect of gefitinib. PMC5354947
HCC4006 100 nM 24 h To evaluate the effect of AZ1366 in combination with gefitinib on transcriptional changes, results showed that AZ1366 significantly enhanced the transcriptional changes induced by gefitinib. PMC5354947

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice PC9-OR cell xenograft model Oral 5mg/kg Once daily for 71 days To evaluate the effect of Osimertinib in combination with Aurora kinase inhibitor MLN8237 on tumor growth, results showed that the combination significantly suppressed tumor growth. PMC6324945
Mice Non-small cell lung cancer xenograft model Oral 5 mg/kg Once daily for 95 days To investigate the resistance mechanisms of Osimertinib in EGFR L858R and T790M mutant non-small cell lung cancer xenograft models. The results showed that continuous Osimertinib treatment led to the emergence of BRAF G7V and PIK3C2A A86fs mutations, along with a decrease in the frequency of EGFR L858R and T790M mutations, resulting in drug resistance. PMC5993147
BALB/cA nude mice NCI-H1975 xenograft model Oral 1, 5, 10 mg/kg Once daily for 21 days To evaluate the in vivo antitumor activity of ASK120067 in the NCI-H1975 xenograft model, the results showed that ASK120067 dose-dependently inhibited tumor growth and caused significant tumor shrinkage at the dose of 10 mg/kg. PMC7218543
mice H1975 xenograft model orally 5 mg/kg 5 days a week for 3 consecutive weeks To evaluate the effect of Osimertinib on tumor volume in vivo, a significant reduction in tumor volume was observed. PMC11068778
Mice Orthotopic NSCLC model Oral 3.125 mg/kg Once daily, 5/7 days To evaluate the effect of osimertinib in combination with AZ1366 on tumor growth and survival, results showed that the combination treatment did not significantly improve survival. PMC5354947

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06530719 Lung Neoplasms|Lung Cancer, No... More >>nsmall Cell Less << PHASE2 NOT_YET_RECRUITING 2025-05-28 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.39mL

1.68mL

0.84mL

16.79mL

3.36mL

1.68mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories